Plus deals involving Abliva/Owl, Selecta/Cartesian, Novo Nordisk/Genevant, AbbVie/Aldeyra and more.

Ondine Biomedical’s method of disinfection is easy to administer, cheap, and does not promote antimicrobial resistance.

Both Atlas and Foresite Capital announced new funds focused on start-ups. Also, Flagship launched Vesalius with $75m in initial funding, Innoviva sold $225m in notes, Hookipa priced a $75m follow-on offering and job cuts were revealed by Epizyme, Flexion, Deciphera and Gemini. 

The market for diagnostic and infection control products will see continued growth as hospitals and other providers look to the technology sector to help fight the battle against health care-associated infections and antibiotic-resistant organisms.